University Hospital Southampton
Southampton, Hants, SO16 6YD, United Kingdom
NCT Number: NCT03766646
If a patient speaks during the process of preoxygenation with high-flow nasal oxygen via the Optiflow™ system, is the efficacy reduced as measured by end-tidal lung oxygen content?
Looking for future studies?
Notify Me18 year–65 year
Female
Interventional
Not applicable
Southampton, Hants, SO16 6YD, United Kingdom
This is a randomised controlled trial on 34 patients undergoing routine elective surgery at the Princess Anne Hospital, Southampton. The study will take place from September 2018 to January 2019 and involve preoxygenating all participants for three minutes using the Optiflow™ device. During this time, participants will be instructed to either read aloud a standardised text or to breathe through their nose with a closed mouth. At the end of 3 minutes, the primary outcome, ETO2, will be measured and recorded.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
45l.min oxygen
Other names: HFNO, High Flow Nasal Oxygen
Time frame: At the end of 3 minutes preoxygenation
Oxygen fraction in first expired breath post preoxygenation
University Hospital Southampton NHS Foundation Trust
Other
Preoxygenation With High Flow Nasal Oxygenation Using Optiflow - Does Speech Have an Effect on The End Tidal Oxygen Achieved When Compared to Closed Mouth Nasal Breathing?
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05132608
Unrecognized Condition
Dhulikhel, Bagmati, Nepal
View Trial DetailsNCT05929053
Behavior, Communication
Merkez, Artvin, Turkey (Türkiye)
View Trial DetailsNCT06464328
Anxiety Disorders, Behavior
Kota Bharu, Kelantan, Malaysia
View Trial DetailsNCT05908604
Unrecognized Condition
Kuopio, Finland
View Trial Details